Praxis Precision Medicines, Inc.2024财年第三财季实现净利润-51.91百万美元，同比减少110.76%

市场透视11-15

11月15日，Praxis Precision Medicines, Inc.（PRAX.US）公布财报，公告显示公司2024财年第三财季净利润为-51.91百万美元，同比减少110.76%；其中营业收入为302000.00美元，同比减少35.47%，每股基本收益为-2.75美元。从资产负债表来看，Praxis Precision Medicines, Inc.（PRAX.US）总负债33.59...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483683385?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-15 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483683385","market":"us","top_or_hot":-1,"title":"Praxis Precision Medicines, Inc.2024财年第三财季实现净利润-51.91百万美元，同比减少110.76%","media":"市场透视","content":"<div>\n<p>11月15日，Praxis Precision Medicines, Inc.（PRAX.US）公布财报，公告显示公司2024财年第三财季净利润为-51.91百万美元，同比减少110.76%；其中营业收入为302000.00美元，同比减少35.47%，每股基本收益为-2.75美元。从资产负债表来看，Praxis Precision Medicines, Inc.（PRAX.US）总负债33.59...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000120abc18905&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines, Inc.2024财年第三财季实现净利润-51.91百万美元，同比减少110.76%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines, Inc.2024财年第三财季实现净利润-51.91百万美元，同比减少110.76%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000120abc18905&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月15日，Praxis Precision Medicines, Inc.（PRAX.US）公布财报，公告显示公司2024财年第三财季净利润为-51.91百万美元，同比减少110.76%；其中营业收入为302000.00美元，同比减少35.47%，每股基本收益为-2.75美元。从资产负债表来看，Praxis Precision Medicines, Inc.（PRAX.US）总负债33.59...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000120abc18905&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000120abc18905&s=b","article_id":"2483683385","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000120abc18905&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483683385","pubTimestamp":1731600061,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月15日，Praxis Precision Medicines, Inc.公布财报，公告显示公司2024财年第三财季净利润为-51.91百万美元，同比减少110.76%；其中营业收入为302000.00美元，同比减少35.47%，每股基本收益为-2.75美元。机构评级：截至2024年11月15日，当前有10家机构对Praxis Precision Medicines, Inc.目标价做出预测，其中目标均价为145.60美元，其中最低目标价为57.00美元，最高目标价为270.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc."},"translate_title":"Praxis Precision Medicines, Inc. achieved net profit of-51.91 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 110.76%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1},"content_text":"11月15日，Praxis Precision Medicines, Inc.（PRAX.US）公布财报，公告显示公司2024财年第三财季净利润为-51.91百万美元，同比减少110.76%；其中营业收入为302000.00美元，同比减少35.47%，每股基本收益为-2.75美元。从资产负债表来看，Praxis Precision Medicines, Inc.（PRAX.US）总负债33.59百万美元，其中短期债务1.22百万美元，资产负债比为0.13，流动比率为0.11。机构评级：截至2024年11月15日，当前有10家机构对Praxis Precision Medicines, Inc.目标价做出预测，其中目标均价为145.60美元，其中最低目标价为57.00美元，最高目标价为270.00美元。公司简介：Praxis Precision Medicines Inc 是一家临床阶段的生物制药公司。 该公司致力于将遗传学见解转化为针对受中枢神经系统疾病影响的患者的疗法开发，这些疾病的特征是神经元兴奋-抑制失衡。 该公司的产品线包括 PRAX-114，用于治疗患有严重抑郁症和创伤后应激障碍的广泛患者； PRAX-944，用于治疗特发性震颤和帕金森病； PRAX-562 和 PRAX-222 等。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483683385"}